| scholarly article | Q13442814 |
| P356 | DOI | 10.1136/GUT.26.4.359 |
| P8608 | Fatcat ID | release_fhtulgbw5betrgx66gdqov5qt4 |
| P932 | PMC publication ID | 1432521 |
| P698 | PubMed publication ID | 3979908 |
| P5875 | ResearchGate publication ID | 19181850 |
| P2093 | author name string | Collier DS | |
| Pain JA | |||
| P2860 | cites work | The Effect of 16,16-Dimethyl Prostaglandin E2 on Meal-Stimulated Gastric Acid Secretion and Serum Gastrin in Duodenal Ulcer Patients | Q67756434 |
| Inhibition of gastric secretion by prostaglandins | Q69824226 | ||
| Intravenous indomethacin and aspirin reduce basal gastric mucosal blood flow in dogs | Q71152250 | ||
| Indomethacin and perforated duodenal ulcer | Q71179162 | ||
| Perforated peptic ulcer in south-west Scotland 1966-1980 | Q71690479 | ||
| Genetic Control of Phenylbutazone Metabolism in Man | Q71722353 | ||
| Inhibition of gastric secretion in man by prostaglandin A | Q71805126 | ||
| Influence of Phenylbutazone on Gastric Secretion of Mucus | Q72263715 | ||
| Reappraisal of the effects of aspirin on the stomach | Q72429131 | ||
| 20 years of hospital admissions for peptic ulcer in England and Wales | Q72471935 | ||
| Prophylactic effect of dietary fibre in duodenal ulcer disease | Q72533244 | ||
| Stilboestrol, phenobarbitone, and diet in chronic duodenal ulcer. A factorial therapeutic trial | Q79292143 | ||
| Letter: Coffee, cigarettes and peptic ulcer | Q95780365 | ||
| Civilisation and peptic ulcer | Q28189542 | ||
| Peptic Ulcer in Town and Country | Q33698233 | ||
| Aspirin ingestion and perforated peptic ulcer | Q34475114 | ||
| Incidence of perforated duodenal and gastric ulcer in Oxford | Q35002879 | ||
| Effects of oestrogens and progestogens on gastric secretion in patients with duodenal ulcer | Q35003610 | ||
| Investigation of the vasodilator and antisecretory role of prostaglandins in the rat gastric mucosa by use of non-steroidal anti-inflammatory drugs | Q35174809 | ||
| Epidemiological evidence for the association of aspirin and acute gastrointestinal bleeding | Q39991685 | ||
| Prostaglandin cytoprotection of gastric mucosa | Q40111936 | ||
| Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury | Q41682736 | ||
| What is happening to peptic ulcer? | Q42337328 | ||
| Stimulation of mucus and nonparietal cell secretion by the E2 prostaglandins | Q44088878 | ||
| Cigarette smoking and duodenal-ulcer disease | Q45156718 | ||
| Effect of Age and Sex on Human Drug Metabolism | Q50348052 | ||
| Drug consumption before perforation of peptic ulcer. | Q51050578 | ||
| Inadequacy of the literature on the relationship between drugs, ulcers, and gastrointestinal bleeding. | Q52725958 | ||
| Ascorbic-acid levels in leucocytes of patients with gastrointestinal haemorrhage. | Q54016092 | ||
| Effects of an Orally Administered Prostaglandin Analogue (16,16-Dimethyl Prostaglandin E2) on Human Gastric Secretion | Q67246355 | ||
| Hospital admissions for peptic ulcer during 1958-72 | Q67434393 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 359-363 | |
| P577 | publication date | 1985-04-01 | |
| P1433 | published in | Gut | Q5621669 |
| P1476 | title | Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. | |
| P478 | volume | 26 |
| Q44521605 | A 1-year follow-up of prescribing patterns of analgesics in primary health care |
| Q43901155 | A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis |
| Q42264807 | Abolition by omeprazole of aspirin induced gastric mucosal injury in man. |
| Q67919629 | Acid Peptic Disease in the Elderly |
| Q34378035 | Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection |
| Q69786353 | Anti-inflammatory drugs and upper gastrointestinal ulcer perforation |
| Q47149652 | Are the Symptoms of an NSAID-Induced Ulcer Truly Milder Than Those of an Ordinary Ulcer? |
| Q69924847 | Association between villous atrophy in rheumatoid arthritis and a rheumatoid factor and gliadin-specific IgG |
| Q39462536 | Asymptomatic peptic ulcer disease |
| Q42559696 | Asymptomatic peptic ulcer disease |
| Q36676391 | Asymptomatic peptic ulcer disease. Is it worth looking for? |
| Q34619252 | Changes in the localization of perforated peptic ulcer and its relation to gender and age of the patients throughout the last 45 years |
| Q35231203 | Clinical profile and outcome of surgical treatment of perforated peptic ulcers in Northwestern Tanzania: A tertiary hospital experience |
| Q74829293 | Cost, benefits and unintended gastrointestinal side effects of pharmaceutical therapy |
| Q33432343 | Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002. |
| Q33883996 | Diagnosis and treatment of nonsteroidal anti-inflammatory drug-associated upper gastrointestinal toxicity |
| Q36718215 | Do non-steroidal anti-inflammatory drugs or smoking predispose to Helicobacter pylori infection? |
| Q33562630 | Drug toxicity |
| Q36815067 | Duodenal ulcer perforation: the effect of H2 antagonists? |
| Q34417829 | Effect in man of aspirin, standard indomethacin, and sustained release indomethacin preparations on gastric bleeding |
| Q69487191 | Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs |
| Q72084095 | Efficacy and Upper GI Safety of Diclofenac/Misoprostol, Piroxicam and Naproxen in Patients with Osteoarthritis |
| Q36767875 | Epidemiology and genetics of peptic ulcer |
| Q33603755 | Epidemiology of adverse drug reactions in the elderly by drug class |
| Q43733337 | Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial |
| Q38254644 | Etodolac, a new nonsteroidal anti-inflammatory drug: gastrointestinal microbleeding and endoscopic studies |
| Q45099641 | GI effects of OTC analgesics: implications for product selection. |
| Q43111570 | Gastric anti-ulcerative and anti-inflammatory activity of metyrosine in rats. |
| Q93720362 | Gastrointestinal bleeding in Romford |
| Q33883978 | Gastrointestinal bleeding in older people |
| Q35587778 | Gastrointestinal complications of nonsteroidal anti-inflammatory drugs |
| Q68343279 | Gastrointestinal ulcerations induced by anti-inflammatory drugs in rats. Physicochemical and biochemical factors involved |
| Q74524883 | Gastropericardial fistula with pneumopericardium: an unusual complication of benign peptic ulceration |
| Q46799037 | Giant duodenal ulcer. Evaluation of basal acid output, nonsteroidal antiinflammatory drug use, and ulcer complications |
| Q72897473 | Helicobacter pylori infection, ABO blood group, and effect of misoprostol on gastroduodenal mucosa in NSAID-treated patients with rheumatoid arthritis |
| Q40433048 | High-risk drugs in the elderly population |
| Q40392368 | Histamine H2-receptor antagonists in peptic ulcer disease. Evidence for a prophylactic use. |
| Q34393550 | Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man |
| Q68330627 | Improvement of Absorption Rate of Indomethacin and Reduction of Stomach Irritation by Alginate Dispersions |
| Q69911680 | Incidence of perforated and bleeding peptic ulcers before and after the introduction of H2-receptor antagonists |
| Q42060071 | Influence of age, comorbidity, type of operation and other variables on lethality and duration of post-operative hospital stay in patients with peptic ulcer. An analysis of 303 surgically treated patients |
| Q33557672 | Management of NSAID induced gastrointestinal disturbance |
| Q35920722 | Management of gastroduodenopathy associated with use of nonsteroidal anti-inflammatory drugs |
| Q40403535 | Medical management of rheumatoid arthritis |
| Q34396108 | Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy |
| Q69172637 | Misoprostol reduces gastroduodenal injury from one week of aspirin: an endoscopic study |
| Q57945636 | NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND HOSPITAL ADMISSION FOR PERFORATED PEPTIC ULCER |
| Q36282905 | Non-steroidal Anti-inflammatory Drugs: Monitoring to help prevent serious adverse effects |
| Q36706880 | Non-steroidal anti-inflammatory agents and the gastrointestinal tract |
| Q36526925 | Non-steroidal anti-inflammatory drug associated ulcer: Epidemiology, causation and treatment |
| Q36723729 | Non-steroidal anti-inflammatory drug ingestion: retrospective study of 272 bleeding or perforated peptic ulcers |
| Q69877679 | Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer |
| Q34527487 | Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration |
| Q70016174 | Non-steroidal anti-inflammatory drugs and peptic ulcer perforation |
| Q35167288 | Non-steroidal anti-inflammatory drugs and peptic ulcers |
| Q35707627 | Non-steroidal anti-inflammatory drugs in patients with peptic ulcer disease: to be considered in certain circumstances |
| Q43110475 | Non-steroidal anti-inflammatory drugs--prescribe with caution |
| Q36916782 | Nonsteroidal Anti-inflammatory Drug Toxicity: Increased Risk in the Elderly |
| Q50956118 | Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. |
| Q81445235 | Occult GI bleeding in NSAID users--the base of the iceberg! |
| Q37282622 | PRESENTATION AND MANAGEMENT OF PERFORATED PEPTIC ULCER DISEASE IN A TERTIARY CENTRE IN SOUTH SOUTH NIGERIA. |
| Q81722666 | Peptic ulcer and non-steroidal anti-inflammatory agents |
| Q34529234 | Peptic ulcer and non-steroidal anti-inflammatory agents |
| Q68406057 | Peptic ulcer in rheumatoid arthritis |
| Q50949643 | Peptic ulcer perforation before and after the introduction of H2-receptor blockers and proton pump inhibitors. |
| Q68128966 | Perforated peptic ulcer |
| Q50541429 | Perforated peptic ulcer in Hong Kong and New South Wales |
| Q37254428 | Perforated peptic ulcer: how to improve outcome? |
| Q50596836 | Perforated pyloroduodenal ulcers. Long-term results with omental patch closure and parietal cell vagotomy. |
| Q69873500 | Perforated ulcer in the elderly |
| Q34379031 | Predicting NSAID related ulcers--assessment of clinical and pathological risk factors and importance of differences in NSAID |
| Q40844869 | Prescribing policy for antiulcer treatment in the elderly |
| Q35704624 | Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine |
| Q38678800 | Prostaglandins in the gut and their relationship to non-steroidal anti-inflammatory drugs |
| Q34527888 | Randomised study of the influence of non-steroidal anti-inflammatory drugs on the treatment of peptic ulcer in patients with rheumatic disease |
| Q43492439 | Ranitidine prevents duodenal ulcers associated with non-steroidal anti-inflammatory drug therapy |
| Q93770586 | Reply |
| Q93770721 | Reply |
| Q40816610 | Rheumatoid arthritis in the aged. Incidence and optimal management |
| Q69877701 | Rising frequency of ulcer perforation in elderly people in the United Kingdom |
| Q37611782 | Risk factors for adverse drug reactions--epidemiological approaches |
| Q38596275 | Role of endogenous prostaglandins in preventing gastrointestinal ulceration: induction of ulcers by antibodies to prostaglandins. |
| Q45040803 | Serum values of pepsinogens and antibodies to Helicobacter pylori in relation to a history of peptic ulcer disease and NSAID use. |
| Q57386566 | Side-effects of non-steroidal anti-inflammatory drugs |
| Q38596287 | Silent peptic ulceration: deadly silence or golden silence? |
| Q50618471 | Society stress and peptic ulcer perforation. |
| Q37882609 | Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates? |
| Q73384533 | The British Society of Gastroenterology Diamond Jubilee. March 1997 |
| Q44779582 | The Management of Non-Steroidal Anti-Inflammatory Drug-Induced Gastroduodenal Ulcers |
| Q36972832 | The Problems and Pitfalls of NSAID Therapy in the Elderly (Part II)1 |
| Q72674430 | The consequences of H2 receptor antagonist--piroxicam coadministration in patients with joint disorders |
| Q39521994 | The gastrointestinal side effects of the nonsteroidal anti-inflammatory drugs |
| Q28367917 | The histopathology of non-steroidal anti-inflammatory drug induced gastroduodenal damage: correlation with Helicobacter pylori, ulcers, and haemorrhagic events |
| Q37717322 | The management of NSAID gastropathy |
| Q34561025 | Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. |
| Q41526041 | Toxicity of Nonsteroidal Anti-Inflammatory Drugs in the Elderly: Is Advanced Age a Risk Factor? |
| Q41683130 | Traumatic and nontraumatic perforation of hollow viscera |
| Q38709591 | Treatment of peptic ulcer disease in the arthritic patient |
| Q41190759 | Treatment of peptic ulcer in the elderly. Proton pump inhibitors and histamine H2 receptor antagonists |
| Q42106342 | Two cheers for NSAIDs |
| Q58386266 | Ulcer Bleeding and Perforation: Non-steroidal Anti-inflammatory Drugs orHelicobacter pylori |
| Q39557962 | Variability in response to NSAIDs. Fact or fiction? |
| Q41905119 | Variations in response to non-steroidal anti-inflammatory drugs |
| Q55041186 | Why not have definitive trials of gastrointestinal safety for non-steroidal anti-inflammatory drugs? Discussion paper. |
| Q67979617 | [Epidemiology and treatment of gastroduodenal lesions caused by non-steroidal anti-inflammatory agents] |
| Q49947619 | pH-responsive CAP-co-poly(methacrylic acid)-based hydrogel as an efficient platform for controlled gastrointestinal delivery: fabrication, characterization, in vitro and in vivo toxicity evaluation |
Search more.